KSQ Doses First Patient in CRISPR TIL Therapy Trial
KSQ Therapeutics has dosed the first patient in a Phase 1/2 clinical trial for KSQ-004EX, a CRISPR-engineered tumor-infiltrating lymphocyte...
Digital Lung Simulations in Pulmonary Fibrosis Drug Development
Ebenbuild’s Twinhale technology, a software for creating digital lung twins, was used in a preclinical study on idiopathic pulmonary...
Inna-051 Antiviral Phase 2 Study: Respiratory Disease Breakthrough
ENA Respiratory is partnering with the University of Maryland’s Center for Vaccine and Global Development (CVDGH) to conduct a...
Assembly Biosciences Presents New Data on Herpes Simplex Virus Candidate at ESCMID
Assembly Biosciences presented data at the 2025 ESCMID Congress on ABI-5366, a novel, long-acting helicase-primase inhibitor candidate for recurrent...
MN-166 ALS Trial: First Patient Enrolled in NIH-Funded EAP
MediciNova has enrolled the first patient in a National Institutes of Health (NIH)-funded Expanded Access Program (EAP) to evaluate...
Annexon at AAN: GBS Data & New Education Campaign
Annexon, Inc. presented Phase 3 trial data for tanruprubart (formerly ANX005), a C1q-blocking monoclonal antibody, at the 2025 AAN...
Cerevance’s CVN293 Shows Positive Phase 1 Results at AAN 2025
Cerevance announced positive Phase 1 trial results for CVN293, a novel KCNK13 inhibitor targeting neuroinflammation. The drug was well-tolerated...
Sellas Announces Positive Survival Results in AML Trial
SELLAS Life Sciences announced positive Phase 2 trial data for SLS009 (tambiciclib), a CDK9 inhibitor, in relapsed/refractory acute myeloid...
OPGX-LCA5 Gene Therapy Shows Promising One-Month Data in Pediatric Retinal Disease Trial
Opus Genetics announced positive one-month data from the first pediatric patient in its Phase 1/2 trial of OPGx-LCA5, a...
Recursion Doses First Patient in Phase 1 MALT1 Inhibitor Study
Recursion Pharmaceuticals has dosed the first patient in a Phase 1 clinical trial, EXCELERIZE, for REC-3565, a potential best-in-class...